Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV
· Real-Time Price · USD
1.82
0.04 (2.25%)
At close: Aug 15, 2025, 3:59 PM
1.91
4.95%
After-hours: Aug 15, 2025, 07:55 PM EDT
Enlivex Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.45M | -5.18M | -2.6M | -3.1M | -4.14M | -9.1M | -5.96M | -6.79M | -7.22M | -7.19M | -5.73M | -9.91M | -8.22M | -4.74M | -3.42M | -3.11M | -3.2M |
Depreciation & Amortization | 90K | 36K | 161K | 160K | 188K | 200K | 214K | 212K | 209K | 221K | 192K | 176K | 188K | 150K | 157K | 122K | 117K |
Stock-Based Compensation | 293K | n/a | 377K | 388K | 383K | 400K | 407K | 511K | 633K | 757K | 470K | 697K | 788K | 1.7M | 377K | 652K | 190K |
Other Working Capital | -192K | -52.99K | -1.29M | 911K | -1.13M | 705.83K | 499K | -1.63M | -551K | 202K | 773K | -2.69M | 1.35M | -387K | -1.26M | -1.14M | 990K |
Other Non-Cash Items | -1.08M | 392.21K | 944K | 181K | 608K | 2.99M | 216K | 226K | 208K | 202K | -2.69M | 226K | 185K | -3.16M | -542K | -1.14M | -336K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -112.87K | 102K | 234K | 1.39M | n/a | n/a | 2.92M | 1.97M | -3.38M | -629K | -1.2M | -388K |
Change in Working Capital | -470K | 663.79K | -1.5M | 570K | -962K | 993.35K | -415K | -1.41M | -1.01M | 1.19M | 1.16M | -3.38M | 1.83M | -541K | -769K | -936K | 889K |
Operating Cash Flow | -4.62M | -4.08M | -2.62M | -1.8M | -4.51M | -5.03M | -5.44M | -7.02M | -5.78M | -4.82M | -6.59M | -9.27M | -3.27M | -6.59M | -4.2M | -4.41M | -2.34M |
Capital Expenditures | -32K | -35K | -9K | -16K | -43K | -5.94K | -29K | -38K | -162K | -2.58M | -1.19M | -3.4M | -952K | -1.03M | -120K | -299K | -173K |
Cash Acquisitions | n/a | 303.51K | n/a | n/a | 224K | 48.92K | -1.27K | 80.68K | n/a | -10.66K | -45.23K | 1.45M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -9.54M | -1.27M | -12.45M | -10.14M | -8.48M | 4.04M | 3.97M | -3.03M | -31.18M | 10.96K | 35.23M | -34.92M | -1.92M | -14.08M | -4.64M | -15.94M | -69.75M |
Sales Maturities Of Investments | 12.41M | 4.38M | 12.08M | 9.32M | 13.4M | 11.52K | -4.45K | 288K | n/a | -295K | 10M | -1.41M | 62.55M | 9.77M | 19.09M | 28.44M | 10.34M |
Other Investing Acitivies | 336K | -21.19K | 1.77M | 34.91K | 53K | 4.14K | 5.72K | 1.32K | -31.18K | -295 | 45.23K | -34.92K | 60.63K | -4.31K | 14.45K | 12.5K | -59.42K |
Investing Cash Flow | 3.17M | 3.36M | 1.4M | -794K | 5.1M | 4.1M | 3.94M | -2.7M | -31.35M | -2.88M | 44.04M | -38.32M | 59.67M | -5.35M | 14.32M | 12.2M | -59.59M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3 | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 2K | n/a | 40.51K | n/a | n/a | n/a | n/a | n/a | n/a | 50K | 50K | 50K | n/a | 67K | 2K | 7.74M |
Financial Cash Flow | 197K | 1.26M | 250K | 4.42M | 524K | -1.28K | -5.56K | 42K | 318K | -1.02K | 50K | 50K | 50K | -3K | 67K | 2K | 60.92M |
Net Cash Flow | -1.25M | 535K | -970K | 1.83M | 1.1M | -1.16M | -1.49M | -9.68M | -36.81M | -7.69M | 37.5M | -47.54M | 56.45M | -11.69M | 9.74M | 8.18M | -1.61M |
Free Cash Flow | -4.66M | -4.15M | -2.63M | -1.81M | -4.55M | -5.03M | -5.47M | -7.06M | -5.95M | -7.4M | -7.78M | -12.67M | -4.22M | -7.62M | -4.32M | -4.71M | -2.51M |